Home › Categories › Business & Finance› Novavax

Novavax.pdf

8831-VaxNovavaxFactSheet-004.pdf

🔗 Source: toronto.ca

📊 Size: 136 KB

👤 Author: Toronto Public Health

⬇️ Downloads: 48

Summary

Toronto Public Health provides information on the Novavax Nuvaxovid COVID-19 vaccine, which was approved by Health Canada on December 5, 2023, for people 12 years and older. The vaccine is a protein subunit vaccine that targets the COVID-19 virus, and a single dose is recommended six months after a previous vaccine. Novavax can be used to complete a vaccination series or as a booster dose, and it works well to prevent getting sick from COVID-19, although long-term protection is not yet known. Common side effects include redness, pain, or swelling at the injection site, mild fever, and headache, and serious allergic reactions can occur in rare cases. Individuals with certain health conditions, such as a weakened immune system or autoimmune condition, should speak with a healthcare provider before getting the vaccine.

Download File

Description

Toronto Public Health provides information on the Novavax Nuvaxovid COVID-19 vaccine, which was approved by Health Canada on December 5, 2023, for people 12...

Technical Information

File Format: PDF
File Size: 136 KB
Pages: 3
Language: EN
Author: Toronto Public Health
Total Downloads: 48
Last Updated: 4 weeks ago

Document Overview

This PDF document about Novavax provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into Novavax.